Patisiran Comprehensive Forecast on the Accelerating Market Growth for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Patisiran, providing insights into the drug market landscape and market forecast of Patisiran up to 2034.

Are you interested in finding out the projected market size of Patisiran in 2034? Patisiran Market Forecast @ https://www.delveinsight.com/sample-request/patisiran-sales-forecast-and-market-size-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Factors Driving Patisiran Growth
1. Market Share Gains and New Patient Starts
• Patisiran (ONPATTRO®) has established itself as a leading RNA interference (RNAi) therapeutic in the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, helping capture a significant share of the small pool of eligible patients within this ultra-rare disease segment since its initial approval in 2018.
• Steady new patient starts are driven by increasing diagnosis rates for hATTR amyloidosis and greater physician awareness around TTR-targeted therapies, especially in key markets such as North America and Europe where specialty care centers are active.
• Alnylam's broader RNAi portfolio and targeted education efforts have helped reinforce ONPATTRO's position among clinicians treating amyloid neuropathy, supporting continued adoption within a niche but medically critical segment.

2. Expansion across Key Indications
• Hereditary ATTR Amyloidosis with Polyneuropathy: ONPATTRO's primary approved indication remains treatment of the polyneuropathy associated with hATTR amyloidosis in adults, where it helps reduce pathogenic transthyretin (TTR) protein levels through mRNA silencing.
• Beyond this core indication, patisiran has been under clinical investigation for ATTR amyloidosis with cardiomyopathy, with positive Phase III APOLLO-B data suggesting clinical benefits and supportive biomarker effects - although regulatory expansion of this indication is currently on hold.
• Long-term extension data have shown sustained slowing of disease progression in familial amyloid polyneuropathy (FAP), emphasizing the importance of early treatment initiation and expanded therapeutic impact over years.

For More Information about Patisiran Market Report @ https://www.delveinsight.com/sample-request/patisiran-sales-forecast-and-market-size-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Patisiran Market Report offers projected sales forecasts for Patisiran for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

Patisiran Drug Summary
Patisiran (Onpattro) is a lipid nanoparticle-formulated small interfering RNA (siRNA) approved for the treatment of polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis in adults, a rare autosomal dominant disorder caused by TTR gene mutations leading to misfolded transthyretin protein that forms amyloid deposits in peripheral nerves, autonomic nerves, heart, and other tissues, resulting in progressive sensorimotor neuropathy, autonomic dysfunction, and cardiomyopathy. Administered as a 0.3 mg/kg intravenous infusion every 3 weeks following premedication with dexamethasone, retinoids, acetaminophen, and an H1/H2 antagonist to mitigate infusion-related reactions, patisiran targets wild-type and mutant transthyretin mRNA in hepatocytes via RNA interference: the siRNA is taken up by ApoE-opsonized lipid nanoparticles through receptor-mediated endocytosis, processed by Dicer to form the RNA-induced silencing complex (RISC), which cleaves complementary TTR mRNA to reduce serum transthyretin protein levels by ~80-90% within 2-3 weeks, halting new amyloid formation, stabilizing neuropathy (as shown in the APOLLO trial with mNIS+7 improvement), improving quality of life, and potentially benefiting cardiac amyloidosis. The report provides Patisiran's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Patisiran Market Recent Developments
FDA Complete Response Letter on Expanded Indication (2023): The US FDA issued a Complete Response Letter for patisiran's supplemental NDA seeking approval for the cardiomyopathy indication, stating that evidence did not meet the threshold for clinical meaningfulness. As a result, Alnylam discontinued this expansion effort in its then-submitted form, though ONPATTRO's core indication remains unaffected. Positive APOLLO-B Data Presentations: Additional data from the APOLLO-B Phase III study - including sustained treatment effects at 18-24 months on functional outcomes and quality of life measures - have been presented at scientific congresses, underlining ongoing interest in patisiran's potential beyond its current label.

Do you want to know more information of this report? @ https://www.delveinsight.com/sample-request/patisiran-sales-forecast-and-market-size-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

What is Patisiran Prescribed for?
Patisiran is prescribed for the treatment of Hereditary Transthyretin-Mediated Amyloidosis (hATTR amyloidosis) in adults, particularly in patients who develop polyneuropathy associated with the disease. hATTR amyloidosis is a rare genetic disorder caused by mutations in the transthyretin (TTR) gene, leading to the accumulation of abnormal amyloid protein deposits in various tissues, including nerves, the heart, and other organs. Patisiran is an RNA interference (RNAi) therapy that works by reducing the production of the transthyretin protein in the liver. By lowering the levels of this protein, the drug helps prevent the formation and deposition of amyloid fibrils that damage nerves and organs.

Patisiran Market Assessment
This report provides a detailed market assessment of Patisiran for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2020 to 2034.

Patisiran Clinical Assessment
The report provides the clinical trials information of Patisiran for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

Do you know your drug's competitive positioning against Patisiran? Patisiran Drugs Insights @ https://www.delveinsight.com/sample-request/patisiran-sales-forecast-and-market-size-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Patisiran Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Patisiran.

Patisiran Market Size in the US
A dedicated section of the report focuses on the expected market size of Patisiran for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Why you should buy Patisiran Market Report
• The report provides future market assessments for Patisiran for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies.
• Leading Patisiran for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Patisiran
• Discover the competitive landscape of Patisiran through 7MM
• Get a Thorough Analysis of the Patisiran Development pipeline, Safety & Efficacy of the Patisiran, and ROA
• Thorough Patisiran market forecast will help understand how drug is competing with other emerging Patisiran
• Get analysis of the Patisiran clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.